Mankind Pharma's Q3 FY 2025-26 Quarterly Results
- 04 Feb 2026
Result Summary
- Mankind Pharma Ltd reported a 3.9% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 10.1%.
- Its expenses for the quarter were down by 4.4% QoQ and up 7.6% YoY.
- The net profit decreased 20.4% QoQ and increased 7.6% YoY.
- The earnings per share (EPS) of Mankind Pharma Ltd stood at 9.89 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 3639.95 | 3789.03 | 3307.32 | -3.9% | 10.1% |
Total Expenses | 3027.57 | 3167.33 | 2813.43 | -4.4% | 7.6% |
Profit Before Tax | 505.79 | 621.70 | 493.89 | -18.6% | 2.4% |
Tax | 95.12 | 103.84 | 112.81 | -8.4% | -15.7% |
Profit After Tax | 413.88 | 520.18 | 384.52 | -20.4% | 7.6% |
Earnings Per Share | 9.89 | 12.38 | 9.44 | -20.1% | 4.8% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Mankind Pharma Ltd is a prominent player in the pharmaceutical industry, primarily engaged in the development, manufacture, and marketing of a diverse range of pharmaceutical products. The company is known for its extensive portfolio of medications, which includes prescription drugs, over-the-counter products, and health supplements. Mankind Pharma has a strong foothold in the Indian pharmaceutical market and has been expanding its reach internationally. The company is committed to innovation and quality, focusing on delivering affordable healthcare solutions. As of the latest data available, no specific major developments or changes in strategy have been prominently reported.
Revenue
During the third quarter of fiscal year 2026 (Q3FY26), Mankind Pharma Ltd reported a total income of ₹3639.95 crores. This represents a decrease of 3.9% compared to the previous quarter (Q2FY26), where the total income was ₹3789.03 crores. However, on a year-over-year basis, the total income increased by 10.1% from ₹3307.32 crores in Q3FY25. The company's revenue performance reflects both the challenges and growth opportunities in the pharmaceutical sector, where fluctuations are commonplace due to factors such as market demand, regulatory changes, and competitive dynamics.
Profitability
In Q3FY26, Mankind Pharma Ltd reported a profit before tax of ₹505.79 crores, which is a decrease of 18.6% from ₹621.70 crores in the previous quarter. The year-over-year comparison shows a modest increase of 2.4% from ₹493.89 crores in Q3FY25. The profit after tax for Q3FY26 was ₹413.88 crores, declining by 20.4% from the previous quarter's ₹520.18 crores, yet up by 7.6% compared to ₹384.52 crores in Q3FY25. The earnings per share for the quarter stood at ₹9.89, down from ₹12.38 in Q2FY26 and slightly higher than ₹9.44 in Q3FY25. This data indicates fluctuations in profitability, often influenced by operational efficiencies, cost management, and market conditions.
Operating Metrics
The total expenses for Mankind Pharma Ltd in Q3FY26 were ₹3027.57 crores, down by 4.4% from the previous quarter's ₹3167.33 crores. Year-over-year, total expenses increased by 7.6% from ₹2813.43 crores in Q3FY25. The tax expense for the quarter was ₹95.12 crores, showing a decrease of 8.4% from Q2FY26 and a reduction of 15.7% from Q3FY25. These operating metrics highlight the company's cost management strategies and their impact on the overall financial performance. The decrease in expenses and tax liabilities quarter-over-quarter suggests adjustments in operations and financial planning.